# Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

> **NCT06663059** · PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle
- **DRUG:** Adebrelimab combined with albumin-bound paclitaxel and cisplatin 4 cycle

## Key facts

- **NCT ID:** NCT06663059
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06663059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06663059, "Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06663059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*